Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 1
Submit an article Journal homepage
208
Views
17
CrossRef citations to date
0
Altmetric
Drug Evaluation

Milatuzumab: a promising new agent for the treatment of lymphoid malignancies

Tomer Mark Weill Medical College of Cornell University, New York Presbyterian Hospital–Cornell Medical Center, Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, 525 East 68th Street, Payson Pavilion, 3rd Floor, NY 10021, USA +1 212 746 3964; +1 212 746 5536; [email protected]; TM and PM contributed equally to this work and share first authorship responsibilities
, MD,
Peter Martin Weill Medical College of Cornell University, New York Presbyterian Hospital–Cornell Medical Center, Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, 525 East 68th Street, Payson Pavilion, 3rd Floor, NY 10021, USA +1 212 746 3964; +1 212 746 5536; [email protected]; TM and PM contributed equally to this work and share first authorship responsibilities
,
John P Leonard Weill Medical College of Cornell University, New York Presbyterian Hospital–Cornell Medical Center, Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, 525 East 68th Street, Payson Pavilion, 3rd Floor, NY 10021, USA +1 212 746 3964; +1 212 746 5536; [email protected]; TM and PM contributed equally to this work and share first authorship responsibilities
, MD &
Ruben Niesvizky Weill Medical College of Cornell University, New York Presbyterian Hospital–Cornell Medical Center, Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, 525 East 68th Street, Payson Pavilion, 3rd Floor, NY 10021, USA +1 212 746 3964; +1 212 746 5536; [email protected]
, MD
Pages 99-104 | Published online: 03 Dec 2008
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Abstract

Background: Non-Hodgkin's lymphoma and multiple myeloma are often incurable and respond to a limited set of treatment options. The selective expression of CD74, the invariant chain of the MHC class II molecule, in these malignancies provides an attractive target for antibody-based therapy. Objective: This review evaluates the preclinical data for milatuzumab, a humanized antibody targeting CD74, as a treatment for non-Hodgkin's lymphomas and multiple myeloma. Methods: A review of the literature was carried out using PubMed. Current Phase I protocols using milatuzumab are summarized. Results/conclusion: Milatuzumab is cytotoxic to lymphoma and multiple myeloma cell lines and mouse–human xenografts. The efficacy dramatically increases when milatuzumab is attached to a toxin or a radioactive agent. Phase I trials of milatuzumab are now underway in human subjects with lymphoma and multiple myeloma.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,464.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.